IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v17y2000i4p383-389.html
   My bibliography  Save this article

Cost Analysis of the Treatment of Schizophrenia in the UK

Author

Listed:
  • Stephen Almond
  • Owen O’Donnell

Abstract

Objective: To compare the costs of 2 atypical drug therapies (olanzapine and risperidone)with one another and with a conventional antipsychotic (haloperidol) in the treatment of schizophrenia. Design and setting: The analysis is based on a simulation model with parameter values taken mainly from clinical trial data in patients with schizophrenia, and was conducted within a UK context. Results: The 3 therapies are approximately cost neutral over a 5-year period (olanzapine £35 701, risperidone £36 590 and haloperidol £36 653). There is evidence of greater efficacy with the atypical drugs [average percentage of 5 years with Brief Psychiatric Rating Scale (BPRS) scores >18: olanzapine 63.6%, risperidone 63.0% and haloperidol 52.2%]. The cost and efficacy differences between the 2 atypical drugs are too small to rank them in terms of cost effectiveness. Extensive sensitivity analysis does not change any of the main conclusions. Conclusions: Given evidence of efficacy gains to the atypical drugs, these represent cost-effective treatment options. Prospective data from nontrial treatment settings would help substantiate the model findings. Copyright Adis International Limited 2000

Suggested Citation

  • Stephen Almond & Owen O’Donnell, 2000. "Cost Analysis of the Treatment of Schizophrenia in the UK," PharmacoEconomics, Springer, vol. 17(4), pages 383-389, April.
    • Handle: RePEc:spr:pharme:v:17:y:2000:i:4:p:383-389
    DOI: 10.2165/00019053-200017040-00008
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200017040-00008
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200017040-00008?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:17:y:2000:i:4:p:383-389. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.